Functional p53 Increases Prostate Cancer Cell Survival after Exposure to Fractionated Doses of Ionizing Radiation

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7190-7196

  Scott, Susan L ^a   Earle, John D ^b,c   Gumerlock, Paul H ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; DNA; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BEAM THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; TEMPERATURE SENSITIVITY; TREATMENT FAILURE; WILD TYPE;

CELL LINE, TUMOR; CELL SURVIVAL; DOSE FRACTIONATION; G1 PHASE; G2 PHASE; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0242526120     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. American Cancer Society. ACS Cancer Facts and Figures 2002, pp. 1-48. Atlanta, GA: American Cancer Society, 2002.
2. NIH. Know Your Options: Understanding Treatment Choices for Prostate Cancer, pp. 1-48. Bethesda, MD: NIH, 2002.
3. Horwitz, E. M., Hanlon, A. L., and Hanks, G. E. Update on the treatment of prostate cancer with external beam irradiation. Prostate, 37: 195-206, 1998.
4. Kirby, R. Treatment options for early prostate cancer. Urology, 52: 948-962, 1998.
5. Dewey, W. C., Ling, C. C., and Meyn, R. E. Radiation-induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 33: 781-796, 1995.
6. Nunez, M. I., McMillan, T. J., Valenzuela, M. T., Ruiz de Almodovar, J. M., and Pedraza, V. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiother. Oncol., 39: 155-165, 1996.
7. Ross, G. M. Induction of cell death by radiotherapy. Endocr.-Rel. Cancer, 6: 41-44, 1999.
8. Leith, J. T. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate, 24: 119-124, 1994.
9. Bernhard, E. J., McKenna, W. G., and Muschel, R. J. Radiosensitivity and the cell cycle. Cancer J. Sci. Am., 5: 194-204, 1999.
10. Dasika, G. K., Lin, S. C., Zhao, S., Sung, P., Tomkinson, A., and Lee, E. Y. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene, 18: 7883-7899, 1999.
11. Molinari, M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif., 33: 261-274. 2000.
12. Offer, H., Zurer, I., Banfalvi, G., Reha, K. M., Falcovitz. A., Milyavsky, M., Goldfinger, N., and Rotter, V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res., 61: 88-96, 2001.
13. Smith, M. L., Chen, I. T., Zhan, Q., and Bae, I. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science (Wash. DC), 266: 1376-1380, 1994.
14. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
15. 2 arrest after DNA damage. Science (Wash. DC), 282: 1497-1501, 1998.
16. 2/M checkpoint. Genes Dev., 14: 1584-1588, 2000.
17. Chan, T. A., Hermeking, H., Kinzler, K. W., and Vogelstein, B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature (Lond,), 401: 616-620, 1999.
18. 2/M progression. Mol. Cell, 1: 3-11, 1997.
19. 2 phase. J. Biol. Chem., 275: 22627-22630, 2000.
20. Fan, S., El-Diery, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, L., Fornace, A. J., Macgrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res., 54: 265-270, 1994.
21. Mirzayans, R., Aubin, R., Bosnich, W., Blattner, W. A., and Peterson, M. C. Abnormal pattern to post-γ-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. Br. J. Cancer, 71: 1221-1230, 1995.
22. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
23. Ng, C. E., Banerjee, S. K., Pavliv, M., Wang, G., Raaphorst, G. P., and Aubin, R. A. p53 status, cellular recovery and cell cycle arrest as prognosticators of in vitro radiosensitivity in human pancreatic adenocarcinoma cell lines. Int. J. Radiat. Biol., 75: 1365-1376, 1999.
24. Little, J. B. Changing views of cellular radiosensitivity. Radiat. Res., 140: 299-311, 1994.
25. Aldridge, D. R., and Radford, I. R. Explaining differences insensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res., 58: 2817-2824, 1998.
26. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
27. Biard, D. S. F., Martin, M., Le Rhun, Y., Duthu, A., Lefaix, J. L., May, E., and May, P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364, 1994.
28. O'Connor, P. M., Jackman, J., Jondle, D., Kishor, B., Macgrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
29. Ribiero, J. C. C., Barnetson, A. R., Fisher, R. J., Mameghan, H., and Russell, P. J. Relationship between radiation response and p53 status in human bladder cancer cells. Int. J. Radiat. Biol., 72: 11-20, 1997.
30. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
31. Jung, M., Notaro, V., and Dritschilo, A. Mutations in the p53 in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52: 6390-6393, 1992.
32. Kyprianou, N., King, E. D., Bradbury, D., and Rhee, J. G. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells, Int. J. Cancer, 70: 341-348, 1997.
33. Garzotto, M., Haimovitz-Friedman, A., Liao, W-C., White-Jones, M., Huryk, R., Heston, W. D., Cardon-Cardo, C., Kolesnick, R., and Fuks, Z. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res., 59: 5194-5201, 1999.
34. Coffey, R. N. T., Watson, R. W., Hegarty, P. K., Watson, C. L., Wolohan. L., Brady, H. R., O'Keane, C., and Fitzpatrick, J. M. Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases. Cancer (Phila.), 92: 2297-2308, 2001.
35. Chi, S-G., deVere White, R. W., Meyers, F. J., Siders, D. B., Lee, F., and Gumerlock, P. H. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. (Bethesda), 86: 926-933, 1994.
36. Carroll, A. G., Voeller, H. J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123-134, 1993.
37. Rubin, S. J., Hallahan, D. E., Ashman, C. R., Brachman, D. G., Becket, M. A., Virudachalam, S., and Yandell, D. W. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol., 46: 31-36, 1991.
38. Shi, X-B., Nesslinger, N. J., Deitch, A. D., Gumerlock, P. H., and deVere White, R. W. Complex functions of mutant p53 alleles from human prostate cancer. Prostate, 51: 59-72, 2002.
39. Mack, P. C., Gandara, D. R., Bowen, C., Edelman, M. J., Paglieroni, T., Schnier, J. B., Gelman, E. P., and Gumerlock, P. H. RB status as a determinant of response to UCN-01 in non-small cell lung cancer. Clin. Cancer Res., 5: 2596-2604, 1999.
40. Gumerlock, P. H., Meyers, F. J., Kokoris, S. P., Wong, G., McCormick, F. P., and deVere White, R. W. Ras enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal. Biochem., 180: 158-168, 1989.
41. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
42. Walker, K. K., and Levine, A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA. 93: 15335-15340, 1996.
43. Voeller, H. J., Sugars, L., Pretlow, T., and Gelmann, E. P. p53 oncogene mutations in human prostate cancer specimens. J. Urol., 151: 492-495, 1994.
44. Bullock, A. N., and Fersht, A. R. Rescuing the function of mutant p53. Nat. Rev. Cancer, 1: 68-76, 2001.
45. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
46. Tang, H-Y., Zhao, K., Pizzolato, J. F., Fonarev, M., Langer, J. C., and Manfredi, J. J. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. J. Biol. Chem., 273: 29156-29163, 1998.
47. 1 arrest in resulting tetraploid cells. Cancer Res., 61: 7660-7668, 2001.
48. 2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. USA, 96: 2147-2152, 1999.
49. 2/M transition by p53. Oncogene, 20: 1803-1815, 2001.
50. Hall, E. J. Radiobiology for the Radiologist. Philadelphia: Lippincott Williams & Wilkins, 2000.
51. Zellers, R. C., Naida, J. D., Davis, M. A., and Lawrence, T. S. Effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiat. Oncol. Investig., 5: 43-49, 1997.
52. Pollock, R., Lang, A., Ge, T., Sun, D., Tan, M., and Yu, D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin. Cancer Res., 4: 1985-1994, 1998.
53. van Laar, T., Schouten, R., Jochesem, A. G., Terleth, C., and van der Eb, A. J. Temperature-sensitive mutant p53 (Ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells. Cytometry, 25: 21-31, 1996.
54. WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene, 11: 2311-2316, 1995.
55. Gallo, O., Chiarelli, I., Bianchi, S., Calzolari, A., Simonetti, L., and Porfirio, B. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin. Cancer Res., 2: 1577-1582, 1996.